Immunogenicity & Immunotoxicity
Immunotherapeutics & Immunomonitoring
Cytokines & Inflammation
GTCbio is proud to present the 9th Immunotherapeutics & Immunomonitoring Conference, to be held on February 6-7, 2017 in San Diego, CA.
The immune system plays a central role not only in fighting infections, but also in many diseases and medical conditions, including cancer. Studies of the immune system has led to significant findings in many fields of medicine and biology, which has yielded the discovery of novel and unique substances and reagents that are now widely used for diagnosing, evaluating, and treating different malignant diseases. The development of prophylactic and therapeutic vaccines, and innovative combinatorial immunotherapeutic approaches, has substantially decreased mortality, increased life expectancy, improved life expectancy and improved the well-being of the millions of patients.
Leading scientific and clinical experts from academia and industry will present the latest findings and developments in the exciting area of immunotherapeutics and immunomonitoring. New immunological concepts with clinically translational implications will be discussed, along with evaluations of novel drug targets and therapeutic approaches, the role of biomarkers in immunomonitoring, and the latest data on combinatorial treatments in the clinic.
Network with colleagues to discuss updates on state-of-the-art immunomonitoring, novel strategies to identify and validate biomarkers predictive for clinical efficacy, novel strategies to identify and clinically develop synergistic combination therapies, and the outlook on novel druggable targets for immunotherapy.
I. Emerging Targets in Immune Therapeutics
II. Conditioning the Tumor Microenviroment for Immunotherapy
III. Immunomonitoring & Novel High Throughput Technologies
IV. Combination Immunotherap
We hope to see you there!
The 2017 Organizing Committee
What Past Delegates said:
“The GTC conference definitely provided a private, common, and friendly setting to exchange ideas and opinions with industry and academia leaders. Networking really happens at this conference with relevant and exciting topics. I left the GTC conference with fresh ideas and with new connections for future partnerships.” – Mario Pulido, PhD Student, USC
“The topics covered in the 4th Immunotherapeutics and Immunomonitoring Conference were targeted and provided an excellent balance between clinical and basic research. Moreover, the intimate setting was an ideal environment to foster collaboration.” – Fatema Legrand, Associate Director, Clinical Immunology, BN Immunotherapeutics
“The GTC Immunotherapeutics Summit was a great opportunity to meet industry and academic leaders. The networking opportunities were ideal for meaningful exchanges and setting up potential collaborations.” – Yoav Peretz Ph.D., Principal Scientist, ImmuneCarta Services
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
ACEA Biosciences, Inc. is a pioneer in the development and commercialization of highperformance microelectronic systems for cell-based assays. ACEA’s xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
SQI Diagnostics is a life sciences company that provides clinical grade multiplexed assays and its automated instrumentation to the pharmaceutical research market. SQI develops custom ADA, epitope mapping, multiplexed PK assays, biomarker, and many other assays all in one well making it the leader in the multiplexing of therapeutic proteins, isotypes and subclasses in a single well.
Our goal is simply to help researchers gain a better understanding of proteins and their role in disease. We develop and commercialize proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Our goal is to make protein analysis simpler, more quantitative and affordable. Our comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.
Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines.
Euro Diagnostica offers versatile assay solutions and cutting-edge tools to pharma, biotech and CRO customers. Facilitating the development of safe and efficient drugs as well as an optimal treatment of patients, Euro Diagnostica is an optimal partner during the whole drug development continuum.
AllCells is a biotechnology company that provides hematological/immunological tissue products and expertise in bioservices worldwide. Our products include clinical grade tissue and primary cells, diseased cells, and whole blood for scientific research use. AllCells is fully certified in accordance with local, state and federal requirements and was established in 1998.
Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.
Fidelta is a preclinical CRO offering services in ADME, Medicinal Chemistry, in vivo, in vitro and translational projects. We focus on the therapeutic areas involved in Respiratory, Inflammation, Fibrosis, Invectives and Oncology. Besides our standard models and assays, we also offer customized development and validation.
SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.
ABL, Inc. is a CMO/CRO with facilities in the US and Europe that provides diverse services for biologics development and manufacturing (protein and viral). ABL offers; PD, GMP manufacturing, preclinical and clinical development, comprehensive immunological services, clinical immunogenicity testing, GCLP trial sample processing and testing and many other services. www.ablinc.com
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.